vaccin
confer
immun
protect
infecti
agent
diverg
arm
adapt
immun
respons
elabor
antibodi
humor
immun
system
highli
effect
neutral
mani
bacteria
virus
fungi
parasit
cellmedi
immun
respons
also
play
major
role
contain
infecti
agent
lymphocyt
compris
divers
set
cell
function
activ
depend
helper
cell
elabor
varieti
cytokin
stimul
b
cell
produc
antibodi
induc
format
cytotox
lymphocyt
ctl
ctl
recogn
process
antigen
major
histocompat
complex
mhc
molecul
lyse
infect
cell
humor
cellular
immun
elicit
vaccin
effector
function
inactiv
pathogen
differ
way
tabl
although
humor
immun
respons
well
known
confer
protect
role
ctl
protect
immun
viral
infect
recogn
recent
function
specif
cell
provid
foundat
understand
mhc
restrict
import
protect
viral
infect
cellular
immun
respons
help
control
infecti
diseas
particularli
difficult
gener
neutral
antibodi
patient
acquir
immunodefici
syndrom
aid
malaria
tuberculosi
humor
immun
readili
induc
purifi
protein
inactiv
virus
togeth
appropri
adjuv
genebas
vaccin
appear
particularli
effect
induc
tcell
respons
time
genebas
vaccin
induc
humor
immun
respons
use
specif
vector
specif
primeboost
combin
varieti
vector
nonvir
viral
develop
purpos
figur
common
review
major
adjuv
use
vaccin
develop
affect
humor
immun
appear
enhanc
antibodi
respons
without
induc
cellular
immun
contrast
genebas
vaccin
vector
stimul
humor
cellular
immun
thu
provid
greater
select
pressur
infecti
agent
chapter
major
genebas
vaccin
progress
clinic
trial
summar
togeth
advantag
disadvantag
individu
vector
influenc
differ
effector
arm
immun
system
although
consider
experi
inactiv
virus
proteinbas
vaccin
develop
genebas
vaccin
vector
infanc
abil
induc
cellular
immun
immunogen
safeti
mode
antigen
present
attract
featur
counter
limit
knowledg
clinic
efficaci
product
methodolog
concern
antivector
immun
tabl
nevertheless
like
vector
make
unpreced
contribut
vaccinolog
futur
possibl
vaccin
nake
dna
gener
excit
earli
four
independ
group
simultan
report
plasmid
gene
deliveri
could
result
vivo
antigen
express
result
immun
respons
plasmidencod
antigen
stephan
johnson
laboratori
use
devic
call
gene
gun
shoot
gold
bead
coat
plasmid
encod
human
growth
hormon
gene
therapi
techniqu
mice
surprisingli
anim
seroconvert
gene
therapi
group
attempt
har
power
plasmid
vaccin
purpos
present
work
session
cold
spring
harbor
vaccin
meet
fall
laboratori
margaret
liu
merck
harriet
robinson
univers
massachusett
vaccin
mice
intramuscularli
plasmid
express
influenza
antigen
show
antigenspecif
immun
could
induc
david
weiner
univers
pennsylvania
report
plasmid
contain
hiv
envelop
tumor
antigen
capabl
drive
cellular
humor
immun
respons
mice
novel
result
combin
simplic
obviou
manufactur
util
dna
spawn
research
dna
vaccin
plethora
viral
bacteri
parasit
cancer
target
dna
vaccin
platform
perceiv
scientif
commun
import
conceptu
dna
multipl
advantag
tradit
live
attenu
kill
peptidebas
viral
vector
vaccin
exampl
dna
easi
manipul
combin
simplic
synthet
chemistri
bacteri
product
power
genom
allow
rapid
design
construct
potenti
vaccin
remov
entir
requir
develop
vaccin
use
pathogenderiv
materi
second
dna
vector
extrem
stabl
reduc
need
cold
chain
increas
product
shelf
life
therefor
eas
stabil
cost
effect
platform
make
ideal
manufactur
vaccin
develop
world
furthermor
dna
vector
immunogen
allow
repeat
homolog
vaccin
without
immun
interfer
importantli
dna
vaccin
combin
immun
power
live
replic
vaccin
induct
broad
cellular
humor
immun
respons
safeti
eas
manufactur
nonliv
nonspread
platform
dna
vaccin
nonrepl
elimin
risk
attenu
revers
spread
subject
unintend
secondari
infect
vaccin
popul
constraint
dna
vaccin
product
develop
repeatus
manufactur
facil
thu
provid
enorm
save
product
develop
manufactur
impli
safeti
advantag
implicit
dna
vaccin
technolog
far
translat
clinic
dna
provid
unparallel
safeti
profil
past
decad
half
clinic
studi
safeti
profil
allow
expand
studi
platform
develop
vaccin
atrisk
group
includ
subject
compromis
immun
elderli
person
chemotherapi
understand
mechan
dna
vaccin
induc
antigenspecif
immun
consider
import
put
simpli
antigen
sequenc
interest
optim
insert
mammalian
express
plasmid
vector
clinic
use
vector
tend
share
specif
featur
includ
highcopynumb
origin
replic
product
purpos
human
cytomegaloviru
immediateearli
cmvie
promot
drive
express
vivo
rna
polyadenyl
sequenc
usual
deriv
bovin
growth
hormon
similar
sequenc
facilit
ribosom
function
plasmid
growth
select
sequenc
limit
kanamycin
bacteri
gene
nonantibiot
select
sequenc
maintain
stabl
express
plasmid
interest
product
plasmid
vaccin
deliv
skin
intraderm
muscl
one
sever
deliveri
method
insid
cytoplasm
cell
plasmid
enter
nucleu
transfect
local
cell
eg
myocyt
keratinocyt
local
resid
antigen
present
cell
apc
insid
cell
plasmidencod
sequenc
drive
host
cell
transcript
result
product
foreign
antigen
vivo
hostsynthes
antigen
becom
subject
immun
surveil
context
mhc
class
class
ii
molecul
vaccin
host
specif
differ
dna
vaccin
live
infect
dna
antigen
deliveri
remain
local
plasmid
transfect
cell
littl
spread
antigen
express
region
bodi
plasmid
live
inert
repres
focus
antigen
epitop
multipl
antigen
pathogen
rather
entir
pathogen
exact
detail
dna
vaccineinduc
immun
remain
subject
debat
intramuscular
im
inject
common
mode
dna
vaccin
deliveri
shown
induc
tcell
respons
limit
antibodi
product
im
inject
like
myocyt
directli
transfect
vaccin
dendrit
cell
transfect
muscl
also
shown
effici
crosspres
antigen
activ
ctl
may
play
role
activ
mhc
restrict
cell
intramuscular
vaccin
altern
apc
muscl
directli
transfect
express
antigen
via
mhc
pathway
activ
ctl
contrast
im
inject
intraderm
id
administr
report
result
robust
humor
respons
consist
antibodi
product
dermi
rich
apc
langerhan
dendrit
cell
may
enhanc
vaccineinduc
immun
id
vaccin
like
im
vaccin
may
result
apc
transfect
antigen
secret
mhc
class
present
mhc
class
ii
present
crossrepresent
present
apc
also
constantli
sampl
environ
endocytosi
result
uptak
secret
antigen
express
predominantli
mhc
class
ii
cell
addit
activ
apc
express
chemokin
may
enhanc
immun
cell
traffick
activ
antigenspecif
cell
substanti
work
continu
area
excit
around
dna
vaccin
studi
preclin
model
quickli
led
studi
human
first
clinic
dna
vaccin
studi
initi
earli
goal
studi
evalu
safeti
toler
immun
potenc
platform
studi
examin
divers
dna
vaccin
varieti
prophylact
therapeut
applic
includ
first
influenza
cancer
antigen
hepat
b
malaria
other
although
initi
dna
vaccin
studi
human
demonstr
excel
toler
safeti
immun
respons
elicit
weaker
expect
basi
preclin
data
stimul
concern
technolog
immun
potenc
concern
drove
develop
import
primeboost
field
combin
immun
focu
dna
platform
immun
expans
power
live
recombin
vaccin
platform
highli
attenu
live
recombin
poxvirus
includ
nyvac
modifi
vaccinia
ankara
mva
alvac
canarypoxbas
vector
import
recombin
adenovir
platform
great
interest
although
viral
platform
induc
strong
antigenspecif
cellular
respons
preclin
model
preexist
poxviru
adenoviru
immun
report
diminish
immun
respons
induc
immun
match
recombin
vaccin
vector
limit
potenc
vector
multipledos
regimen
furthermor
issu
regard
preexist
immun
also
possibl
problemat
dna
approach
could
induc
small
focus
immun
respons
could
expand
subsequ
boost
recombin
vector
encod
antigen
dna
vaccin
combin
view
boon
develop
focus
immun
respons
strategi
first
suggest
studi
murin
model
malaria
dna
prime
follow
mva
nyvac
boost
induc
higher
tcell
respons
either
platform
deliv
alon
schneider
cowork
use
malaria
vaccin
report
prime
dna
mva
led
enhanc
immun
greater
protect
efficaci
achiev
either
vaccin
prepar
alon
find
quickli
extend
mani
dna
plu
recombin
vector
combin
import
shivsiv
simianhuman
immunodefici
viru
simian
immunodefici
viru
model
vaccin
studi
use
dna
prime
follow
recombin
mva
boost
report
induc
cellmedi
immun
respons
impress
magnitud
nonhuman
primat
result
decreas
viremia
viral
challeng
heterolog
dna
primeboost
immun
becam
popular
present
simpl
avail
option
improv
immun
respons
two
differ
vaccin
platform
result
robust
level
vaccinespecif
cellular
humor
immun
potent
immunogen
anim
human
infecti
diseas
abil
induc
cellular
immun
without
humor
immun
rel
eas
product
mani
viral
nonvir
vector
earli
clinic
evalu
heterolog
primeboost
vaccin
mcconkey
colleagu
illustr
benefit
studi
malaria
antigen
vaccin
test
deliveri
antigen
cassett
plasmid
follow
id
deliveri
recombin
modifi
mva
dnamva
combin
safe
induc
cellular
immun
respons
provid
partial
protect
irradiatedsporozoit
malaria
challeng
human
dna
primepoxvir
boost
one
prefer
strategi
well
boost
adenovir
vector
recombin
protein
antigen
among
other
studi
geovax
biotechnolog
compani
collabor
hiv
vaccin
trial
network
hvtn
show
dna
prime
follow
mva
boost
human
drive
high
level
tcell
respons
hiv
antigen
level
antibodi
respons
move
vaccin
program
forward
nih
vaccin
research
center
vrc
report
phase
trial
use
dna
prime
recombin
adenoviru
serotyp
vector
boost
demonstr
approach
induc
cellular
humor
immun
respons
hiv
antigen
current
focus
phase
studi
evalu
regimen
dna
prime
follow
boost
abil
prevent
infect
reduc
viral
load
studi
particip
becom
infect
vaccin
possibl
advantag
heterolog
primeboost
regimen
induct
respons
differ
induc
repeat
dose
either
vaccin
modal
specif
report
cox
colleagu
show
cellular
respons
hiv
vaccin
express
gag
pol
nef
heterolog
regimen
induc
greater
gagspecif
tcell
respons
induc
homolog
regimen
human
furthermor
studi
schneider
cowork
robinson
colleagu
heterolog
dnapoxviru
primeboost
immun
strategi
found
tcell
respons
gener
heterolog
dnapoxviru
strategi
produc
immun
respons
time
higher
either
platform
given
separ
taken
togeth
studi
establish
heterolog
dna
primeboost
immun
elicit
immun
respons
greater
breadth
achiev
prime
boost
vector
overal
strategi
central
role
mani
vaccin
effort
target
divers
difficult
pathogen
mani
approach
taken
improv
immun
respons
induc
dna
vaccin
platform
tabl
includ
optim
promot
region
transcript
element
plasmid
backbon
aim
improv
antigen
express
level
improv
leader
sequenc
optim
plasmid
backbon
develop
improv
gene
sequenc
inclus
molecular
adjuv
formul
immun
modul
develop
varieti
nextgener
deliveri
approach
mani
area
review
highlight
later
dna
technolog
highli
malleabl
contribut
systemat
attack
basic
platform
question
recent
yield
muchimprov
dna
vaccin
immun
profil
major
area
address
plasmid
construct
design
includ
optim
promot
enhanc
element
polyadenyl
incorpor
leader
sequenc
vector
design
antibiot
resist
select
sequenc
origin
replic
choic
product
effici
slimmer
backbon
design
delet
extran
dna
sequenc
contribut
improv
platform
perform
import
consider
increas
plasmiddriven
immun
potenc
involv
sequenc
optim
bacteri
rna
rich
au
sequenc
wherea
mammalian
dna
rich
gc
therefor
pool
trna
need
translat
human
cell
favor
sequenc
enrich
gc
redund
codon
usag
uniqu
transcript
differ
exist
bacteria
divers
virus
parasit
even
host
tumor
antigen
may
benefit
attent
genet
design
dna
sequenc
codonoptim
favor
trna
pool
avail
human
cell
allow
encod
mrna
effici
translat
perhap
even
import
modif
rna
optim
chang
made
rna
sequenc
affect
amino
acid
sequenc
final
vaccin
antigen
exampl
sequenc
rich
gc
like
form
secondari
structur
slow
translat
lower
vivo
protein
product
rna
optim
also
involv
remov
intern
cisact
motif
tata
box
repeat
sequenc
caus
instabl
cryptic
splice
site
unwant
ribosom
bind
site
combin
gene
optim
strategi
dramat
posit
effect
protein
express
vaccin
immunogen
recent
studi
examin
improv
approach
clinic
exampl
studi
west
nile
viru
vaccin
dna
use
improv
promot
induc
relev
antibodi
respons
trial
particip
studi
extend
find
report
trial
sever
acut
respiratori
syndrom
sar
ebola
plasmid
vaccin
result
posit
serolog
induc
vaccin
lower
tcell
respons
major
advantag
dna
platform
abil
rapidli
custom
vaccin
antigen
high
precis
address
specif
vaccin
design
limit
exampl
divers
hiv
envelop
sequenc
reach
greater
within
subtyp
greater
clade
similar
divers
issu
plagu
influenza
hepat
c
viru
hcv
malaria
vaccin
develop
among
other
therefor
vaccin
singl
viral
sequenc
unlik
drive
divers
respons
necessari
crossprotect
varieti
sequenc
circul
popul
approach
overcom
limit
combin
comput
predict
immunogen
design
synthet
chemistri
gener
vaccin
antigen
improv
natur
import
approach
includ
consensu
antigen
ancestor
gene
centeroftre
design
mosaic
antigen
epitop
string
approach
approach
seek
focu
immun
respons
induc
synthet
gene
cassett
specif
epitop
region
nativ
antigen
antigen
predict
comput
analysi
conserv
invari
popul
strategi
seek
maxim
crossreact
tcell
respons
induc
diverg
strain
pathogen
consensu
antigen
mosaic
antigen
epitop
string
current
studi
clinic
studi
highli
inform
dna
vaccin
approach
particularli
suit
deliv
geneencod
adjuv
modul
result
immun
respons
adjuv
deriv
host
gene
known
biolog
allow
unpreced
level
insight
adjuv
choic
unlik
tradit
adjuv
molecular
adjuv
deliv
plasmidencod
vector
part
along
antigenencod
vector
vaccin
molecular
adjuv
vector
transduc
cell
site
vaccin
secret
adjuv
molecul
local
thu
coordin
tempor
target
region
apc
drain
lymph
node
granulocytemacrophag
colonystimul
factor
gmcsf
white
blood
cell
growth
factor
consider
adjuv
properti
one
first
gene
adjuv
clearli
demonstr
cytokin
plasmid
could
modul
dna
vaccineinduc
immun
mice
vaccin
rabi
viru
antigen
dna
addit
gmcsf
increas
antibodi
product
tcell
respons
protect
lethal
challeng
accordingli
gmcsf
becam
wide
studi
dna
molecular
adjuv
examin
macaqu
human
clinic
studi
malaria
vaccin
howev
human
studi
adjuv
effect
clear
initi
anim
studi
remain
investig
part
new
deliveri
format
primeboost
anoth
cytokin
gene
interleukin
il
also
receiv
great
deal
attent
dna
vaccin
adjuv
strong
thelper
cell
type
adjuv
expand
tcell
immun
includ
tcell
function
mous
model
increas
tcell
lysi
target
cell
fold
vaccin
nonhuman
primat
demonstr
increas
cellular
respons
correspond
control
viremia
improv
clinic
outcom
challeng
abil
vector
adjuv
increas
respons
dna
vaccin
current
studi
clinic
hvtn
adjuv
effect
plasmidcodeliv
enhanc
deliveri
appear
promis
addit
tcell
growth
expans
factor
shown
posit
result
mous
macaqu
model
system
move
human
test
eas
specif
combin
adjuv
approach
dna
vaccin
arena
gener
enorm
amount
studi
import
cytokin
gene
costimulatori
molecul
chemokin
gene
heat
shock
antigen
immun
modul
molecul
like
area
continu
receiv
great
deal
attent
particularli
basi
earli
posit
effect
report
clinic
dna
vaccin
deliv
without
benefit
viral
vector
coat
facilit
host
cell
attach
entri
suffer
intrins
limit
transfect
effici
compound
similar
lack
replic
spread
potenti
therefor
major
area
research
focus
improv
dna
entri
target
cell
vivo
extent
efficaci
dna
vaccin
improv
increas
dosag
plasmid
human
wherea
earli
studi
human
use
dosag
mg
less
dosag
mg
use
shown
increas
consist
frequenc
antibodi
product
recent
moreconcentr
formul
dosag
high
mg
togeth
cytokin
express
vector
electropor
stimul
increas
tcell
respons
promis
approach
formul
includ
novel
transfect
reagent
major
focu
earli
studi
addit
physic
deliveri
becom
import
area
research
import
area
dna
deliveri
formul
dna
biodegrad
polymer
microparticl
see
review
well
liposom
applic
microparticleand
liposomebas
deliveri
system
dna
vaccin
technolog
well
match
util
deliveri
enhanc
immunogen
sever
differ
host
antigen
vaccin
platform
shown
small
anim
nonhuman
primat
studi
human
cmv
influenza
applic
compound
dual
role
facilit
plasmid
entri
cell
well
provid
adjuv
effect
polyethyleneimin
aminefunction
polymethacryl
cation
poli
ester
poloxam
polyvinylpyrrolidon
polym
import
exampl
molecul
enhanc
dna
vaccin
immun
potenc
specif
system
poloxam
demonstr
improv
immun
potenc
preclin
model
simian
hiv
vaccin
fact
vaxfectin
relat
deliveri
molecul
exhibit
enhanc
antibodi
respons
dna
vaccin
influenza
recent
clinic
studi
addit
polym
ongo
studi
shown
liposom
vehicl
improv
dna
vaccineinduc
immun
respons
studi
gener
support
greater
effect
antibodi
respons
improv
tcell
respons
liposom
structur
versatil
regard
result
vesicl
surfac
charg
cation
anion
liposom
made
size
lipid
content
codeliveri
adjuv
offer
abil
custom
specif
dna
applic
formul
dna
vaccin
polyamin
gel
nanoparticl
also
report
increas
uptak
plasmid
vector
increas
antigen
express
vivo
great
deal
basic
research
area
howev
approach
trail
liposom
polym
approach
clinic
develop
trajectori
major
area
research
start
bear
fruit
combin
dna
vaccin
physic
deliveri
method
concept
simplephys
forc
plasmid
dna
cell
improv
express
mani
studi
support
idea
improv
immun
respons
gener
sever
simpl
deliveri
devic
gene
gun
biolist
jet
inject
jet
inject
involv
use
high
pressur
deliv
liquid
formul
dna
millimet
centimet
skin
surfac
major
limit
clinic
use
jet
inject
requir
larg
amount
dna
dna
degrad
highpressur
deliveri
howev
rel
simpl
techniqu
shown
improv
immun
respons
compar
needl
syring
experiment
model
system
uniqu
gene
gun
use
high
pressur
deliv
dnacoat
gold
nanoparticl
dermi
although
gene
gun
demonstr
high
transfect
effici
enhanc
antibodi
respons
sever
speci
includ
human
rel
littl
effect
toward
improv
cellular
immun
electropor
ep
use
transfect
cell
vitro
three
decad
recent
use
vivo
increas
transfect
effici
dna
vaccin
ep
involv
appli
small
electr
field
across
site
inject
caus
temporari
membran
instabl
creat
electr
gradient
increas
plasmid
uptak
cell
field
techniqu
studi
two
decad
method
improv
deliveri
chemotherapi
drug
kill
specif
tumor
cell
studi
mani
anim
speci
eg
dog
pig
cattl
nonhuman
primat
deliveri
gene
encod
varieti
hormon
cytokin
enzym
antigen
howev
condit
requir
ep
consid
harsh
adopt
prophylact
modal
past
year
ep
technolog
much
develop
lead
devic
capabl
perform
intramuscular
intraderm
microneedl
transfect
vivo
one
excit
develop
largeanim
model
ep
increas
cellular
humor
immun
respons
combin
optim
approach
magnitud
immun
respons
gener
combin
dna
approach
increas
log
ep
technolog
also
fine
tune
particular
dna
vaccin
modal
devic
control
differ
current
voltag
time
set
develop
combin
molecular
adjuv
look
highli
promis
deliveri
skin
muscl
also
test
importantli
ep
safe
studi
clinic
mani
year
work
need
area
data
primat
model
earli
report
clinic
appear
encourag
initi
movement
dna
vaccin
clinic
demonstr
safeti
manufactur
advantag
platform
limit
platform
induct
standalon
immun
respons
also
appar
mani
initi
safeti
concern
address
appear
risk
associ
dna
vaccin
rel
low
compar
approach
initi
fear
dna
vaccin
risk
integr
activ
oncogen
inactiv
tumor
suppressor
gene
howev
studi
demonstr
rate
dna
integr
vivo
actual
three
time
lower
rate
spontan
mutagenesi
addit
neg
effect
induct
autoimmun
transfer
antibiot
resist
marker
observ
renew
clinic
interest
approach
thousand
volunt
receiv
dna
vaccin
without
singl
signific
advers
event
report
slew
technolog
improv
well
primeboost
approach
reinvigor
clinic
studi
dna
vaccin
technolog
fact
number
dna
vaccin
test
clinic
studi
compar
recombin
platform
increas
year
ago
almost
trial
januari
import
trial
immun
target
highlight
tabl
one
area
serv
baromet
relev
experiment
platform
hiv
vaccin
trial
januari
phase
clinic
trial
sponsor
hvtn
ongo
assess
abil
dna
elicit
immun
respons
ultim
prevent
hiv
infect
either
alon
combin
multipl
viral
vector
one
promin
trial
hvtn
phase
studi
enrol
subject
test
safeti
efficaci
dna
vector
prime
follow
adenoviru
serotyp
boost
vaccin
strategi
develop
vrc
anoth
import
phase
studi
conduct
geovax
hvtn
evalu
efficaci
dna
prime
follow
mva
viru
boost
altern
clinic
approach
use
dna
prime
develop
tcell
respons
well
prime
bcell
immun
follow
recombin
protein
boost
gener
morepot
antibodi
respons
preliminari
data
studi
encourag
import
hiv
studi
standalon
dna
product
test
protocol
hvtn
studi
multipli
optim
dna
plu
adjuv
test
particular
formul
pennvax
dna
preliminari
data
studi
shown
clear
induct
tcell
immun
absenc
viral
vector
boost
import
see
trend
show
improv
immun
respons
clinic
induc
ep
strategi
continu
would
expand
applic
dna
platform
addit
research
hiv
activ
research
studi
dna
vaccin
technolog
prevent
immun
therapi
cancer
hcv
cmv
infect
unit
state
current
activ
dna
vaccin
studi
human
variou
form
cancer
includ
one
phase
immunotherapi
trial
dnaliposom
complex
encod
allogen
mhc
gene
metastat
melanoma
least
four
trial
advanc
phase
studi
phase
studi
includ
two
analys
therapeut
vaccin
men
prostat
cancer
one
melanoma
one
colorect
cancer
two
four
studi
intraderm
electropor
use
increas
immunogen
import
phase
studi
conduct
determin
abil
therapeut
cmv
vaccin
transvax
poloxamerformul
bival
dna
vaccin
contain
plasmid
encod
hcmv
tegument
phosphoprotein
major
hcmv
surfac
glycoprotein
b
produc
safe
immun
respons
provid
clinic
benefit
cmvseroposit
recipi
undergo
allogen
hematopoiet
cell
transplant
result
studi
broad
impact
field
although
success
human
clinic
product
yet
achiev
clear
preced
discuss
technolog
drive
field
well
interest
field
increas
see
tabl
progress
clinic
trial
close
watch
present
excit
pictur
next
year
first
efficaci
trial
dna
approach
come
fruition
anoth
relev
area
commerci
success
dna
technolog
anim
health
product
licens
veterinari
use
includ
dog
melanoma
immun
therapi
porcin
recombin
growth
hormon
vaccin
prevent
rhabdoviru
diseas
fish
west
nile
viru
vaccin
hors
base
success
field
trial
dna
vaccin
risk
associ
dna
vaccin
appear
low
conceptu
practic
thousand
clinic
volunt
receiv
dna
vaccin
without
signific
advers
event
report
import
safeti
record
grow
consist
immun
respons
clinic
success
licensur
veterinari
product
suggest
dna
vaccin
pois
becom
import
safe
platform
continu
vaccin
develop
advanc
molecular
virolog
facilit
understand
regul
viral
replic
gene
express
molecular
pathogenesi
time
understand
enabl
develop
novel
viral
vector
use
vaccin
varieti
vector
advanc
preclin
clinic
studi
see
figur
depend
abil
target
apc
abil
develop
packag
line
inher
immunogen
vector
insert
factor
see
tabl
viral
vector
help
improv
vaccin
efficaci
varieti
infecti
diseas
model
properti
promis
vector
current
progress
develop
summar
follow
section
among
viral
vector
shown
promis
abil
elicit
protect
immun
recombin
adenovir
vector
demonstr
immunogen
protect
immun
varieti
anim
model
virus
genet
modifi
deliv
express
specif
recombin
gene
product
unabl
grow
henc
replicationdefect
like
dna
vaccin
vector
transduc
cell
synthes
nativ
gene
product
appear
quit
potent
abil
induc
helper
specif
ctl
immun
major
clinic
vector
deriv
although
human
serotyp
six
subfamili
af
known
deriv
c
subfamili
common
beststudi
serotyp
howev
rel
high
preval
immun
human
popul
may
pose
limit
use
vector
preexist
immun
may
inhibit
respons
vaccin
immun
altern
serotyp
chimer
vector
develop
circumv
attract
immun
follow
success
varieti
preclin
anim
model
human
trial
phase
respect
anim
model
replicationdefect
adenoviru
shown
elicit
potent
immun
respons
protect
ebola
viru
administ
either
alon
singl
inject
primeboost
combin
primeboost
approach
induc
potent
durabl
immun
desir
prevent
vaccin
routin
use
wherea
singl
rad
vaccin
induc
rapid
respons
suffici
immedi
protect
figur
latter
approach
may
use
contain
acut
outbreak
ebola
infect
could
applic
pathogen
addit
vaccin
dna
boost
combin
shown
confer
partial
protect
rhesu
macaqu
multipl
hiv
isol
includ
replicationdefect
adenoviru
also
use
varieti
addit
anim
model
infecti
diseas
includ
plagu
anthrax
influenza
malaria
phase
clinic
studi
replicationdefect
adenovir
vector
develop
independ
merck
research
laboratori
nih
vrc
nation
institut
allergi
infecti
diseas
merck
vaccin
use
vector
encod
gag
pol
nef
gene
clinic
efficaci
studi
product
call
step
trial
began
evalu
effect
vaccineinduc
tcell
respons
gene
product
intern
viru
control
viral
load
despit
immunogen
vaccin
reduct
acquisit
longterm
control
postinfect
viremia
observ
analys
reveal
person
specif
human
lymphocyt
antigen
hla
type
well
develop
tcell
respons
certain
gag
nef
hiv
epitop
select
virus
contain
vaccin
epitop
vivo
also
unexpect
associ
infect
vaccin
recipi
uncircumcis
immun
vaccin
rate
hiv
infect
first
month
immun
regimen
higher
subgroup
associ
wane
time
mechan
broader
clinic
signific
find
remain
unknown
clinic
util
dna
boost
vaccin
yet
defin
although
prove
efficaci
anim
model
siv
challeng
addit
current
vaccin
contain
env
constitu
includ
merck
vaccin
clinic
vaccin
candid
differ
multipl
way
ongo
phase
hvtn
clinic
trial
provid
insight
potenti
efficaci
despit
abil
induc
potent
sustain
immun
respons
varieti
infecti
pathogen
concern
remain
preexist
immun
may
compromis
efficaci
immun
found
particular
certain
region
africa
seropreval
greater
high
degre
neutral
antibodi
although
cellular
humor
immun
respons
contribut
immun
like
neutral
antibodi
play
major
role
suppress
immunogen
immun
respons
observ
human
preexist
immun
reduc
immunogen
ad
vaccin
mice
rhesu
monkey
potenti
human
clear
preexist
immun
human
complet
block
vaccin
immunogen
reduct
gagspecif
respons
induc
recipi
seen
initi
merck
hiv
vaccin
trial
less
strike
express
immunogen
vector
improv
similarli
vrc
trial
dna
prime
follow
boost
signific
immun
respons
observ
individu
sever
strategi
develop
overcom
potenti
problem
rad
immun
novel
method
deliv
exist
recombin
ad
vector
explor
exampl
possibl
administr
higher
dose
recombin
vector
may
overcom
immun
although
strategi
may
limit
increas
toxic
dose
escal
ad
boost
dna
prime
may
potenti
reduc
immunosuppress
effect
efficaci
approach
human
remain
determin
final
administr
vector
mucos
rout
may
help
circumv
problem
howev
safeti
approach
particularli
intranas
deliveri
yet
determin
addit
sever
investig
explor
possibl
coat
particl
chemic
polyethylen
glycol
may
block
access
antibodi
viral
surfac
altern
approach
evas
immun
includ
engin
vector
evad
domin
immun
respons
varieti
chimer
fiber
hexon
protein
describ
maintain
immunogen
evad
neutral
antibodi
fiber
use
hexon
chimera
appear
target
major
neutral
antibodi
respons
anoth
approach
antivector
immun
involv
develop
novel
vector
altern
serotyp
develop
vector
investig
evalu
rad
vector
lowseropreval
human
adenovirus
well
nonhuman
primat
recombin
ad
vector
human
serotyp
well
describ
seropreval
ad
serotyp
suggest
subfamili
well
adenovirus
subfamili
includ
uncommon
human
may
therefor
offer
advantag
vector
novel
vector
base
develop
preclin
studi
suggest
resist
immun
mice
use
vector
compar
although
altern
vector
show
less
seroposit
often
also
less
immunogen
preclin
anim
studi
also
appear
region
differ
seroposit
divers
rare
serotyp
rad
vector
exampl
although
b
serotyp
shown
promis
earli
clinic
trial
seropreval
low
north
america
seroposit
virus
approach
part
africa
complic
develop
regulatori
issu
vector
addit
replicationincompet
ad
vector
replicationcompet
vector
use
vaccin
vector
either
immun
adenoviru
infect
recombin
vectorsfor
exampl
hiv
vaccin
offer
altern
serotyp
also
deliv
immun
stimulu
gut
mucosa
may
potenti
desir
effect
protect
diseas
final
recombin
ad
vector
develop
altern
speci
includ
sheep
pig
cow
macaqu
chimpanze
conclus
immunogen
rad
vector
prompt
develop
candid
vaccin
varieti
infecti
diseas
vector
well
toler
highli
immunogen
moder
dose
whether
frequenc
preexist
immun
may
compromis
use
human
remain
determin
howev
varieti
strategi
develop
overcom
effect
found
novel
deliveri
vector
well
molecularli
engin
develop
altern
ad
serotyp
human
speci
provid
number
option
expand
use
futur
efficaci
vaccinia
viru
vaccin
vector
repres
one
best
document
exampl
vaccin
infecti
diseas
basi
safeti
issu
recogn
experi
use
vaccinia
strain
smallpox
number
altern
vaccinia
viru
strain
develop
immun
vehicl
avoid
complic
sever
highli
attenu
viru
vaccin
vector
describ
well
avipox
smallpox
vector
strain
summar
box
develop
attenu
vaccinia
virus
also
promot
use
deliveri
vector
gene
product
specif
pathogen
smallpox
use
vector
explor
extens
varieti
infecti
diseas
model
one
two
major
attenu
strain
poxviru
modifi
vaccinia
ankara
develop
repeat
passag
ankara
strain
primari
chicken
embryo
fibroblast
cef
origin
develop
safer
altern
vaccinia
viru
vaccin
smallpox
result
abil
viru
replic
effici
varieti
nonavian
cell
type
multipl
genet
chang
facilit
propag
use
vector
second
altern
attenu
strain
new
york
vaccinia
strain
nyvac
develop
genet
modif
viral
genom
includ
delet
open
read
frame
associ
virul
host
rang
copenhagen
strain
nyvac
like
mva
attenu
anim
model
show
favor
safeti
immunogen
anim
human
viru
also
show
block
earli
stage
replic
though
abl
replic
product
african
green
monkey
kidney
cell
primari
cef
avipox
vector
includ
fowlpox
canarypox
well
alvac
alvac
deriv
plaquepurifi
viru
isol
exist
canarypox
strain
canapox
alvac
abl
express
insert
transgen
shown
immunogen
anim
earli
clinic
trial
vector
evalu
alon
primeboost
combin
varieti
infecti
diseas
cancer
model
see
review
poxvirus
notabl
larg
genom
size
abil
express
recombin
gene
without
effect
replic
capac
polyval
recombin
use
immun
experiment
anim
prove
use
varieti
infecti
diseas
model
includ
rabi
measl
siv
canin
distemp
respiratori
syncyti
viru
malaria
influenza
addit
vector
studi
varieti
hiv
challeng
model
preclin
studi
human
human
studi
undertaken
vaccinia
nyvac
alvac
vector
advanc
efficaci
studi
human
alvacenvgagpol
clade
b
ae
evalu
combin
protein
boost
phase
studi
thailand
trial
demonstr
reduct
frequenc
acquisit
hiv
infect
among
vaccin
heterosexu
men
women
compar
control
placebo
group
studi
repres
landmark
trial
provid
proof
concept
vaccin
could
prevent
infect
although
degre
efficaci
modest
requir
improv
attain
signific
public
health
benefit
poxviru
vector
also
evalu
cancer
immunotherapi
protocol
although
attenu
poxvector
evalu
varieti
human
studi
clear
develop
vaccin
use
human
challeng
part
may
recombin
transgen
repres
small
minor
gene
product
express
otherwis
larg
vector
thu
certainti
immun
respons
focus
foreign
transgen
rather
gene
product
synthes
endogen
poxviru
addit
seen
rad
concern
antivector
immun
remain
viru
well
although
may
lesser
concern
canarypox
vector
poxviru
vector
show
thermost
abil
incorpor
larg
foreign
transgen
lack
persist
genom
integr
demonstr
success
smallpox
erad
howev
difficulti
manufactur
viru
high
yield
primari
cef
well
antigen
complex
reactogen
poor
immunogen
limit
use
human
trial
whether
addit
modif
vector
made
facilit
human
trial
remain
unknown
modif
vector
platform
achiev
vector
may
opportun
contribut
develop
varieti
success
vaccin
adenoassoci
virus
aav
defin
initi
presenc
helper
virus
facilit
propag
wildtyp
adenoviru
cell
cultur
contrast
larg
genom
size
rad
vaccinia
vector
viru
much
limit
size
insert
size
approxim
kb
like
replicationdefect
virus
particl
produc
packag
line
provid
complementari
structur
protein
made
constitut
cell
rather
viru
varieti
serotyp
defin
hiv
vaccin
express
analyz
phase
human
studi
without
evid
strong
immunogen
altern
serotyp
includ
current
develop
may
assess
alon
primeboost
combin
efficaci
human
vector
also
use
recent
deliv
recombin
antibodi
gene
protect
viral
infect
rais
intrigu
possibl
genebas
antibodi
deliveri
might
use
gener
protect
immun
alphavirus
negativestrand
rna
virus
modifi
express
foreign
recombin
gene
without
produc
pathogen
infect
often
seen
prototyp
venezuelan
equin
enceph
viru
sindbi
viru
semliki
forest
viru
replicationdefect
herp
simplex
viru
hsv
produc
use
packag
cell
line
similar
describ
replicationdefect
aav
alphaviru
vector
vaccin
develop
deliv
foreign
gene
potenti
immunogen
also
vector
hsv
includ
recent
vesicular
stomat
viru
dengu
viru
type
yellow
fever
viru
alphaviru
modifi
express
heterolog
viral
gene
vaccin
infecti
diseas
target
includ
hiv
west
nile
viru
filovirus
cmv
pathogen
progress
recent
viral
vector
depend
develop
appropri
packag
cell
line
cell
substrat
viral
product
chang
regulatori
requir
allow
advanc
transform
cell
line
viru
product
prove
invalu
facilit
effort
recombin
adenovir
product
cell
line
support
product
clinicalgrad
adenoviru
type
progress
trial
hiv
studi
infecti
agent
ebola
viru
marburg
viru
tuberculosi
malaria
approv
cell
line
use
divers
vector
cell
line
use
develop
number
vaccin
includ
west
nile
influenza
virus
latter
case
propag
viru
subsequ
inactiv
administr
human
gener
replicationdefect
viral
vector
cell
line
allow
product
vector
use
human
vaccin
studi
virus
develop
vaccin
repres
member
summar
figur
includ
recombin
ad
poxvirus
measl
venezuelan
equin
enceph
viru
aav
progress
human
trial
develop
transform
continu
propagat
cell
line
contrast
previou
standard
avian
leucosisfre
primari
cef
repres
major
advanc
vaccin
product
technolog
larg
cell
line
facilit
product
replicationdefect
viral
vector
stabli
transfect
cell
line
line
also
offer
potenti
improv
yield
stabl
product
capac
develop
line
taken
year
implement
regulatori
concern
regard
adventiti
agent
tumorigen
safeti
consist
consider
oversight
evalu
strength
limit
cell
substrat
continu
base
guidelin
creat
sever
year
ago
increas
number
line
becom
better
character
avail
mani
infecti
agent
replic
mucos
membran
transit
gastrointestin
tract
primari
infect
abil
elicit
effect
immun
respons
site
desir
varieti
bacteria
abl
replic
mucos
site
natur
infect
propos
attenu
microorgan
modif
facilit
deliveri
antigen
might
allow
develop
improv
vaccin
protect
pathogen
enter
mucosa
develop
live
bacteri
vector
therefor
focus
abil
induc
mucos
iga
respons
cytolyt
tcell
respons
mucos
site
deliveri
antigen
mammalian
cell
stimul
antibodi
respons
requir
type
novel
genebas
vaccin
summar
chapter
hand
synthesi
protein
mammalian
cell
deliv
bacteri
vector
potenti
induc
cellular
immun
goal
mani
genebas
viral
nonvir
vaccin
approach
review
detail
elsewher
summar
briefli
among
live
bacteri
vector
use
antigen
deliveri
mucos
pathogen
attenu
includ
strain
listeria
monocytogen
salmonella
vibrio
cholera
shigella
mycobacteria
bovi
yersinia
enterocolitica
bacillu
anthraci
addit
commens
strain
streptococcu
gordonii
lactobacilli
staphylococci
use
induct
humor
cellular
respons
genebas
vaccin
l
monocytogen
particular
focu
research
gramposit
intracellular
pathogen
studi
model
understand
class
mhcrestrict
immun
respons
respons
normal
seen
bacteri
protein
coexpress
antigen
microorgan
use
special
system
introduc
protein
cell
facilit
process
present
mhc
class
differ
mutat
use
develop
attenu
strain
retain
abil
deliv
antigen
similarli
salmonella
bacteri
strain
intracellular
pathogen
becom
restrict
endosom
compart
eukaryot
cell
resist
lysi
varieti
mutat
introduc
salmonella
gener
sever
differ
live
vaccin
carrier
vaccin
prototyp
undergon
develop
vaccin
deliveri
among
bacteri
carrier
bovi
bcg
wide
use
bacteri
vaccin
exampl
organ
use
express
hiv
antigen
instanc
express
mammalian
gene
requir
modif
codon
consist
host
cell
type
improv
immunogen
present
howev
abil
microorgan
induc
cellular
immun
limit
area
intens
interest
use
live
bacteri
vector
deliveri
dna
vaccin
instanc
aim
bacteria
deliv
plasmid
dna
cytoplasm
infect
cell
organ
shigella
listeria
use
purpos
addit
attenu
salmonella
evalu
purpos
shown
promis
infecti
diseas
tumor
model
experiment
anim
although
use
bacteri
vector
attract
theori
difficult
reduc
method
practic
among
concern
possibl
revers
reactogen
potenti
pathogen
bacteria
wild
type
form
stabil
recombin
bacteria
possibl
preexist
immun
exposur
natur
pathogen
may
limit
infect
varieti
host
genet
factor
modul
immun
respons
induc
bacteri
carrier
variabl
innat
immun
respons
pathogen
may
limit
consist
vivo
final
perhap
challeng
problem
abil
effect
gene
transfer
bacteria
mammalian
cell
like
special
transport
pathway
requir
success
implement
technolog
addit
improv
necessari
improv
efficaci
approach
remain
limit
present
form
although
substanti
work
progress
anim
model
vaccin
efficaci
ultim
valu
genebas
vaccin
yet
shown
human
studi
sever
trial
use
poxviru
technolog
advanc
clinic
evalu
includ
canarypox
mva
nyvac
evalu
variou
phase
human
studi
product
technolog
poxvirus
well
known
goodmanufacturingpractic
procedur
amplif
virus
follow
protocol
similar
develop
vaccinia
viru
path
clinic
studi
rel
straightforward
sever
trial
mva
evalu
vaccin
hiv
alon
primeboost
combin
potenti
safer
nextgener
vaccin
smallpox
addit
dna
vaccin
undergon
phase
test
varieti
infecti
diseas
includ
ebola
viru
west
nile
viru
sar
coronaviru
influenza
viru
proofofconcept
efficaci
studi
virus
perform
first
anim
model
either
dna
primeboost
combin
studi
impress
protect
demonstr
base
find
sever
phase
trial
complet
ebola
sar
west
nile
viru
diseas
target
case
influenza
nake
dna
dna
adjuv
gold
microparticl
biolist
advanc
clinic
test
particular
interest
develop
primeboost
strategi
stimul
product
broadli
neutral
antibodi
influenza
virus
demonstr
initi
mice
ferret
monkey
phase
studi
test
concept
human
reveal
even
singl
inject
dna
vaccin
prime
effect
tradit
vaccin
boost
viru
regimen
also
show
broadli
neutral
antistem
antibodi
elicit
vaccin
human
like
licensur
genebas
vaccin
remain
sever
year
futur
recent
two
dna
vaccin
approv
veterinari
use
includ
dna
vaccin
west
nile
viru
hors
develop
fort
dodg
dna
vaccin
infecti
hematopoiet
necrosi
viru
develop
merieux
use
farmrais
fish
addit
vaccin
develop
viral
hemorrhag
septicemia
viru
farm
salmon
studi
singl
inject
microgram
amount
dna
induc
rapid
longlast
immun
protect
recombin
yellow
fever
vaccin
advanc
efficaci
studi
well
preced
set
studi
provid
hope
addit
genebas
vaccin
becom
avail
human
use
may
contribut
develop
protect
immun
varieti
challeng
infecti
diseas
thu
far
elud
grasp
vaccineinduc
immun
